Co-administration of COVID-19 and influenza vaccines

[1]  H. Haslacher,et al.  Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers , 2022, Clinical Microbiology and Infection.

[2]  O. Launay,et al.  Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies , 2022, Human vaccines & immunotherapeutics.

[3]  D. Shay,et al.  Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US , 2022, JAMA network open.

[4]  J. Baillie,et al.  SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses , 2022, The Lancet.

[5]  M. Fournier,et al.  Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study , 2022, The Lancet Respiratory Medicine.

[6]  Adam C. Champion,et al.  Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial , 2021, The Lancet Respiratory Medicine.

[7]  Amy C. Thomas,et al.  Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial , 2021, The Lancet.

[8]  E. Emini,et al.  Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults , 2012, Clinical and Vaccine Immunology.